在阿尔茨海默氏病中使用建模的多纳纳马布暴露和疗效关系
Ivelina Gueorguieva1, Brian A Willis2, Laiyi Chua3
1Eli Lilly and Company Bracknell UK.
Alzheimer's & dementia (New York, N. Y.)
|June 30, 2023
概括
通过减少关键生物标志物如p-tau217和GFAP,多纳尼马布治疗显著减缓了阿尔茨海默病的进展. 这种粉样蛋白向治疗证明了临床疗效,而不考虑基线疾病严重程度.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物标志物研究 生物标志物研究
背景情况:
- 多纳尼马布是一种针对大脑中的粉样蛋白斑块的研究性疗法.
- 阿尔茨海默病 (AD) 的特点是粉样蛋白斑块的积累.
研究的目的:
- 模拟donanemab暴露,血生物标志物和阿尔茨海默病的临床疗效之间的关系.
- 使用药理动力学/药理动力学建模来描述多纳尼马布对疾病进展的影响.
主要方法:
- 利用了阿尔茨海默病患者参与者的第一阶段和TRAILBLAZER-ALZ研究的数据.
- 采用了化217 (p-tau217) 和状纤维化酸性蛋白 (GFAP) 的间接反应模型.
- 开发了结合药理动力学/药理动力学原则的疾病进展模型.
主要成果:
- 多纳尼马布治疗导致p-tau217和GFAP的血度下降.
- 疾病进展模型证实了临床衰退率的显著降低.
- 模拟表明,donanemab减缓了疾病的进展,而不考虑基线tau PET水平.
结论:
- 疾病进展模型表明,多纳尼马布对临床疗效有明显的治疗效果.
- 在减缓疾病进展方面,多纳内马布的疗效显而易见,无论疾病的发病严重程度如何.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.临床痴呆症评分 - 框的总和粉样蛋白质斑块是一种粉样蛋白质斑块.没有的,没有的,没有的.综合性阿尔茨海默氏病评级尺度建模 建模模型 建模模型药理动力学/药理动力学血滑性纤维化酸性蛋白质是血中的一种.化217的化217的化217的化217的化217的化知道的 知道的 知道的更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
相关概念视频
01:22Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220
01:26Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527